WO2000009699A3 - Method for producing yeast expressed hpv types 6 and 16 capsid proteins - Google Patents

Method for producing yeast expressed hpv types 6 and 16 capsid proteins Download PDF

Info

Publication number
WO2000009699A3
WO2000009699A3 PCT/US1999/018016 US9918016W WO0009699A3 WO 2000009699 A3 WO2000009699 A3 WO 2000009699A3 US 9918016 W US9918016 W US 9918016W WO 0009699 A3 WO0009699 A3 WO 0009699A3
Authority
WO
WIPO (PCT)
Prior art keywords
capsid proteins
hpv types
producing yeast
yeast expressed
expressed hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/018016
Other languages
French (fr)
Other versions
WO2000009699A2 (en
WO2000009699A9 (en
Inventor
Daniela Tornese Buonamassi
Catherine E Greer
Cesira L Galeotti
Giuliano Bensi
Roberto Petracca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22258285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000009699(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US09/762,762 priority Critical patent/US7112330B1/en
Priority to AT99940986T priority patent/ATE291089T1/en
Priority to CA2340422A priority patent/CA2340422C/en
Priority to DE69924262T priority patent/DE69924262T3/en
Priority to EP99940986A priority patent/EP1105495B2/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of WO2000009699A2 publication Critical patent/WO2000009699A2/en
Publication of WO2000009699A3 publication Critical patent/WO2000009699A3/en
Publication of WO2000009699A9 publication Critical patent/WO2000009699A9/en
Anticipated expiration legal-status Critical
Priority to US11/404,063 priority patent/US7494787B2/en
Priority to US12/316,310 priority patent/US7897155B2/en
Priority to US13/005,265 priority patent/US20110195506A1/en
Priority to US13/893,821 priority patent/US20140099719A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production conformational antibodies against both L1 proteins upon administration to mice.
PCT/US1999/018016 1998-08-14 1999-08-13 Method for producing yeast expressed hpv types 6 and 16 capsid proteins Ceased WO2000009699A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US09/762,762 US7112330B1 (en) 1998-08-14 1999-08-13 Method for producing yeast expressed HPV types 6 and 16 capsid proteins
AT99940986T ATE291089T1 (en) 1998-08-14 1999-08-13 METHOD FOR PRODUCING YEAST EXPRESSED HPV TYPES 6 AND 16 CAPSID PROTEINS
CA2340422A CA2340422C (en) 1998-08-14 1999-08-13 Method for producing yeast expressed hpv types 6 and 16 capsid proteins
DE69924262T DE69924262T3 (en) 1998-08-14 1999-08-13 METHOD FOR THE PRODUCTION OF YEAST-EXPRESSED HPV TYPS 6 AND 16 KAPSID PROTEINS
EP99940986A EP1105495B2 (en) 1998-08-14 1999-08-13 Method for producing yeast expressed hpv types 6 and 16 capsid proteins
US11/404,063 US7494787B2 (en) 1998-08-14 2006-04-13 Method for producing yeast expressed HPV types 6 and 16 capsid proteins
US12/316,310 US7897155B2 (en) 1998-08-14 2008-12-11 Method for producing yeast expressed HPV types 6 and 16 capsid proteins
US13/005,265 US20110195506A1 (en) 1998-08-14 2011-01-12 Method for producing yeast expressed hpv types 6 and 16 capsid proteins
US13/893,821 US20140099719A1 (en) 1998-08-14 2013-05-14 Method for producing yeast expressed hpv types 6 and 16 capsid proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9662598P 1998-08-14 1998-08-14
US60/096,625 1998-08-14

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09762762 A-371-Of-International 1999-08-13
US09/762,762 A-371-Of-International US7112330B1 (en) 1998-08-14 1999-08-13 Method for producing yeast expressed HPV types 6 and 16 capsid proteins
US11/404,063 Division US7494787B2 (en) 1998-08-14 2006-04-13 Method for producing yeast expressed HPV types 6 and 16 capsid proteins

Publications (3)

Publication Number Publication Date
WO2000009699A2 WO2000009699A2 (en) 2000-02-24
WO2000009699A3 true WO2000009699A3 (en) 2000-05-18
WO2000009699A9 WO2000009699A9 (en) 2000-07-27

Family

ID=22258285

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018016 Ceased WO2000009699A2 (en) 1998-08-14 1999-08-13 Method for producing yeast expressed hpv types 6 and 16 capsid proteins

Country Status (5)

Country Link
EP (1) EP1105495B2 (en)
AT (1) ATE291089T1 (en)
CA (1) CA2340422C (en)
DE (1) DE69924262T3 (en)
WO (1) WO2000009699A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005293A1 (en) * 1994-08-08 1996-02-22 International Centre For Genetic Engineering And Biotechnology Molecular presenting system
WO1998014564A1 (en) * 1996-10-04 1998-04-09 Merck & Co., Inc. Synthetic hpv16 virus-like particles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005293A1 (en) * 1994-08-08 1996-02-22 International Centre For Genetic Engineering And Biotechnology Molecular presenting system
WO1998014564A1 (en) * 1996-10-04 1998-04-09 Merck & Co., Inc. Synthetic hpv16 virus-like particles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANG C ET AL: "Phenotypic mixing between different hepadnavirus nucleocapsid proteins reveals C protein dimerization to be cis preferential", JOURNAL OF VIROLOGY, vol. 68, no. 8, August 1994 (1994-08-01), AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 5225 - 5231, XP002130379 *
HOFMANN K J ET AL: "Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae", JOURNAL OF GENERAL VIROLOGY,GB,SOCIETY FOR GENERAL MICROBIOLOGY, READING, vol. 77, no. 3, March 1996 (1996-03-01), pages 465 - 468, XP000604634, ISSN: 0022-1317 *

Also Published As

Publication number Publication date
EP1105495A2 (en) 2001-06-13
EP1105495B1 (en) 2005-03-16
DE69924262T3 (en) 2009-07-23
WO2000009699A2 (en) 2000-02-24
CA2340422C (en) 2010-03-16
DE69924262T2 (en) 2006-01-26
WO2000009699A9 (en) 2000-07-27
ATE291089T1 (en) 2005-04-15
DE69924262D1 (en) 2005-04-21
EP1105495B2 (en) 2009-01-21
CA2340422A1 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
NO2018010I1 (en) HPV 31 L1 protein
WO2003078455A3 (en) Virus like particle from papillomavirus and their use in vaccine
AU624485B2 (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
WO2000009699A3 (en) Method for producing yeast expressed hpv types 6 and 16 capsid proteins
WO2005047315A3 (en) Optimized expression of hpv 58 l1 in yeast
WO2003077942A3 (en) Virus-like particles of human papillomavirus
WO2005055957A3 (en) Influenza immunogen and vaccine
RU96123707A (en) Papillomavirus vaccines
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
FR11C0022I2 (en) HUMAN PAPILLOMA VIRUS CAPSID PROTEIN PRODUCTION AND VIRAL-LIKE PARTICLES
NO893149L (en) PROCEDURE FOR MICROBIOLOGICAL PREPARATION OF HUMANT SERUM ALBUMIN AND OTHER HETEROLOGICAL PROTEINS FROM YOURS.
CA2370372A1 (en) Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
TW200602490A (en) Optimized expression of HPV 52 L1 in yeast
PT1292328E (en) Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
RU97110164A (en) PREPARED PAPILLOMA VIRUS PROTEINS
RU97116535A (en) METHOD OF PRODUCING BEER
AU2002225509A1 (en) Production and of viruses, viral isolates and vaccines
CA2339324A1 (en) Protein delivery system using human papillomavirus virus-like particles
Woo et al. Expression and purification of human papillomavirus 18 L1 virus-like particle from Saccharomyces cerevisiae
WO2001027282A8 (en) Plant virus particles with exogenous internal eitopes
WO2002004595A3 (en) Production of chimeric human papillomavirus
He et al. Variants of human papillomaviruses 16 (HPV16) in Uigur women in Xinjiang, China
JP2002509863A5 (en)
AU5630590A (en) A clone of double-stranded rna virus applied to antibody production, study of retrovirus-like frameshifting and production of proteins in yeast
WO2000006197A8 (en) Combined vaccine for immunoprophylaxis against viral hepatitis b and d, tetanus and diphtheria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2340422

Country of ref document: CA

Ref country code: CA

Ref document number: 2340422

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999940986

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09762762

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999940986

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999940986

Country of ref document: EP